Melissa Smedley, NP
Family · Lynchburg, TNNPI 1831638691
Payments from drug & device makers
Across 142 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$743
- Novo Nordisk$218
- Pfizer$196
- Lilly USA, LLC$149
- Amgen$91
- UCB, Inc.$80
- plus $688 from 24 others
What the payments were for
- Food & beverage$2,166100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $743 |
| Novo Nordisk | 15 | $218 |
| Pfizer | 10 | $196 |
| Lilly USA, LLC | 10 | $149 |
| Amgen | 4 | $91 |
| UCB, Inc. | 3 | $80 |
| Supernus Pharmaceuticals, Inc. | 4 | $56 |
| Lundbeck LLC | 3 | $54 |
| Neurocrine Biosciences, Inc. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Neurelis, Inc. | 2 | $30 |
| AstraZeneca(2 entities) | 2 | $30 |
| Dexcom, Inc. | 1 | $27 |
| Impel Pharmaceuticals Inc. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Genentech USA, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Novartis | 1 | $13 |
How this compares
$2,166 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 57 | $57,448 |
| OzempicSemaglutide | 52 | $50,304 |
| JanuviaSitagliptin Phosphate | 21 | $29,673 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $22,506 |
| EliquisApixaban | 35 | $21,939 |
| TrulicityDulaglutide | 11 | $20,435 |
| TradjentaLinagliptin | 17 | $18,333 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $13,992 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $11,092 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,419 |
| Bydureon BciseExenatide Microspheres | 11 | $10,232 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,306 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,692 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $5,100 |
| Roflumilast | 15 | $4,382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $30 | $73,73384 claims |
| Novo NordiskOzempic | $218 | $50,30452 claims |
| Boehringer IngelheimTradjenta, Combivent Respimat | $34 | $24,02528 claims |
| PfizerEliquis | $196 | $21,93935 claims |
| Lilly USA, LLCTrulicity | $149 | $20,43511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $1,618196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.
Other family in Lynchburg
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.